Sodium alginate/polyvinylpyrrolidone-gated ZIF-8 nanocarriers for pH-selective sustained docetaxel delivery
Journal of Drug Delivery Science and Technology, cilt.126, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 126
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.jddst.2026.108800
- Dergi Adı: Journal of Drug Delivery Science and Technology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Anahtar Kelimeler: Breast cancer, Docetaxel, pH-dependent release, Polyvinylpyrrolidone, Sodium alginate, ZIF-8
- Erciyes Üniversitesi Adresli: Evet
Özet
Docetaxel (DOC) is a cornerstone in breast cancer chemotherapy, yet its clinical utility is constrained by poor aqueous solubility and systemic toxicity. We report a hybrid nanocarrier that couples an acid-labile zeolitic imidazolate framework-8 (ZIF-8) reservoir with a biocompatible, diffusion-modulating polymer gate composed of sodium alginate (SA)/polyvinylpyrrolidone (PVP) to enable pH-selective, sustained release. The DOC@ZIF-8/SA/PVP composite was synthesized and characterized. XRD confirmed preserved ZIF-8 crystallinity, and FTIR spectra retained characteristic imidazolate bands. Particles showed a unimodal hydrodynamic distribution (hydrodynamic diameter = 184 nm) with a moderately negative zeta potential of −27.6 mV. Nitrogen sorption analysis of pristine ZIF-8 revealed a type I isotherm with a BET surface area of 1171 m2/g and a micropore volume of 0.339 cm3/g, confirming the highly porous nature of the MOF core used for drug loading. In vitro , the coated system exhibited pH-selective sustained release, reaching 95% at pH 5.5 (96–120 h) versus 59% at pH 7.4 (120 h), whereas bare DOC@ZIF-8 released ≤25% (pH 5.5) and 14% (pH 7.4) over the same window. Release kinetics followed the Korsmeyer-Peppas model, indicating a predominantly Fickian diffusion mechanism. In MCF-7 breast cancer cells and NIH3T3 mouse embryonic fibroblasts, DOC@ZIF-8/SA/PVP showed a therapeutic response window between cancer and normal cells, with lower apparent potency than free DOC in MCF-7 cells and reduced toxicity toward NIH3T3 fibroblasts. These findings indicate that the polymer-gated ZIF-8 system improves controlled, pH-selective DOC delivery while reducing normal-cell toxicity, rather than increasing DOC's intrinsic potency. The integration of an MOF reservoir with a polymer gate enables pH-responsive, sustained release of DOC, thereby improving controlled delivery and maintaining biocompatibility in vitro . Overall, the MOF reservoir/polymer gate formulation provides a promising platform for pH-selective DOC delivery and warrants further in vivo evaluation of pharmacokinetics, biodistribution, antitumor efficacy, and safety.